Engflag

Sinutab 3-Way

Quick links to important sections

Sinutab 3-Way

Sinutab 3-Way_EN

Method of action: Analgesic, Anticonvulsant, Anti-Inflammatory, Antipyretic, Antitussive, Cough And Cold Preparations, Nonsteroidal Anti-Inflammatory, Vasoconstrictive

Treatment option: Pain, Headache, Influenza, Fever, Cold

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinutab 3-Way

Property Description
Active Ingredients Ibuprofen, Pseudoephedrine Hydrochloride
Form Oral Tablet or Capsule
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID) and Sympathomimetic Amine
Common Use Multi-symptom relief (pain, fever, nasal congestion)
Origin Synthetic Compound

Sinutab 3-Way is a precise pharmaceutical preparation classified as a fixed-dose combination product, an oral medication designed to deliver simultaneous relief from general pain, fever, and nasal obstruction. This poly-ingredient medicine is synthesized, combining two chemically distinct active compounds into a singular oral form.

What Type of Medicine is Sinutab 3-Way?

Sinutab 3-Way is a combination of two distinct pharmacological classes: a Nonsteroidal Anti-Inflammatory Drug (NSAID) and a Sympathomimetic Amine decongestant. This dual classification defines the drug’s intended purpose, as it is structured to address both systemic discomfort and localized symptoms arising from swelling within the respiratory passages. The fixed-dose format differentiates it from regimens requiring separate sourcing of an NSAID and a decongestant, a characteristic known for simplifying patient adherence during acute symptomatic episodes. The combination of these classes provides effective relief from both nasal congestion and facial pain associated with acute sinusitis.

Composition: Active Ingredients and General Purpose

The medication’s core therapeutic action is derived from its two Active Ingredients: Ibuprofen and Pseudoephedrine Hydrochloride. Ibuprofen serves as the NSAID component, responsible for the drug's fundamental analgesic and antipyretic effects. Conversely, Pseudoephedrine Hydrochloride provides the localized action of a decongestant, which is known to effectively induce vasoconstriction to reduce swelling and edema in the mucous membranes. Pseudoephedrine achieves this by reducing the swelling in the nasal passages, making breathing easier. This specific, synthetic formulation is engineered for multi-symptom relief, serving the general purpose of alleviating the acute physical discomforts of pain, fever, and the pressure associated with nasal congestion, representing a typical, non-prescription option for adults managing cold or flu symptoms.

Regulatory References

  1. Pseudoephedrine Drug Information
  2. Pseudoephedrine Drug Information (NIH)

What side effects are possible with Sinutab 3-Way?

Possible side effects and safety information

The official safety profile for this fixed-dose combination, containing Ibuprofen (an NSAID) and Pseudoephedrine Hydrochloride (a Sympathomimetic Amine), is based on adverse event classifications documented by government regulatory agencies.

Frequency and System-Organ Class

Adverse reactions are formally grouped into System-Organ Classes (SOCs) such as Gastrointestinal Disorders, Nervous System Disorders, and Cardiac and Vascular Disorders. Regulatory classifications indicate that Common adverse reactions typically include gastrointestinal disturbances (like dyspepsia and abdominal pain), insomnia, nervousness, headache, and dizziness. Uncommon reactions may include skin rash and pruritus.

Documented Serious Adverse Reactions

Regulatory documentation highlights serious adverse reactions that require medical evaluation. These include major gastrointestinal bleeding, ulceration, and perforation associated with the NSAID component. The profile also includes the risk of serious Cardiovascular and Cerebrovascular Events such as myocardial infarction, stroke, and hypertensive crisis. Additionally, acute kidney injury and severe hepatic dysfunction are formally listed as possible serious risks.

Safety Considerations and Restrictions

Safety statements note that the risk of serious gastrointestinal events is often highest early in the course of treatment, while cardiovascular risk may be associated with long-term use and high doses. Official restrictions mandate against use in individuals with active peptic ulceration, severe uncontrolled hypertension, severe coronary artery disease, and those with a history of stroke. Specific cautions apply to older adults, who face an increased risk of serious gastrointestinal adverse events.

These classifications, derived from official prescribing information, structure the understanding of the medicine’s risk profile by detailing both frequently reported effects and rare, life-threatening risks across various physiological systems.

Overdose and Emergency Response

Overdose and when to seek help

This section details the officially documented manifestations of an overdose with products containing Ibuprofen and Pseudoephedrine Hydrochloride, and the mandatory emergency actions required by regulatory authorities.

Overdose Scope

Scope Element Regulatory-Aligned Description
Documented overdose presentations Manifestations include signs of CNS depression and stimulation: drowsiness, lethargy, vomiting, and abdominal pain from the Ibuprofen component, alongside restlessness, tachycardia, and anxiety from the Pseudoephedrine component.
Physiological systems affected Primarily the Central Nervous System (CNS) and Cardiovascular System; severe outcomes involve the renal and hepatic systems.
Population-specific overdose notes Children may exhibit increased CNS toxicity, including a higher risk of convulsions. Severity is increased in patients with pre-existing renal/hepatic impairment or severe, uncontrolled hypertension.
Emergency-response statements Immediate medical attention must be sought. Contact a Poison Control Center or emergency services right away.
When immediate medical help is required In cases of suspected overdose, or if symptoms such as seizures, thunderclap headache, severe cardiac arrhythmias, or signs of metabolic acidosis are present.

Overdose Classifications (High-Level)

Classification Element Regulatory-Aligned Description
Severity classification Classified with the potential for severe and life-threatening outcomes, including coma, acute renal failure, and hypertensive crisis.
Regulatory basis Information derived from the mandated Overdose and Management sections of official government prescribing information.
Overdose-context constraints Management is limited to symptomatic and supportive treatment because no specific antidote is known.

Resulting Overdose Structure

Official Overdose Statements:

  • Overdose presents with dual toxicity affecting both the CNS (drowsiness, agitation) and the cardiovascular system (tachycardia, arrhythmias).
  • Severe manifestations include metabolic acidosis, coma, seizures, and life-threatening hypertensive crisis.
  • Immediate medical attention is required for any suspected overdose due to the potential for severe symptoms to develop rapidly.
  • Management is focused on supportive care, including procedures like gastric lavage and activated charcoal, as no specific antidote is known.

Connection to the overall overdose profile: Official regulatory documents define the overdose profile by listing specific, potentially life-threatening clinical manifestations—especially neurological, cardiovascular, and metabolic complications—attributable to the combination of active ingredients. This inherent dual-system risk establishes the non-negotiable condition that immediate medical help must be sought for any suspected exposure exceeding the recommended dose.

Therapeutic Uses of Sinutab 3-Way

What Sinutab 3-Way Treats: Main Uses and Benefits

The medication is commonly used across conditions presenting with acute episodes that involve simultaneous fever, pain, and congestion. It is applied in scenarios where symptomatic relief is needed for the common cold or flu, and may help patients cope more steadily with difficult episodes. It is relevant for addressing headache, fever, sinus pressure, nasal congestion, and minor body aches and pains.

Dual Relief for Systemic Discomfort and Respiratory Obstruction

This medication is generally applied in contexts where additional symptomatic support is needed, primarily targeting the concurrent presence of fever and generalized body aches alongside nasal congestion. It is used when groups of symptoms appear suddenly or fluctuate, and contributes to easing the overall symptom load during acute symptomatic episodes.

Easing Sinus Pressure and Facial Pain

Sinutab 3-Way is relevant for easing symptoms related to localized obstruction, which include sinus pressure and the related facial pain or headache. It is commonly used to help with symptoms that interfere with daily comfort, such as those arising from acute sinusitis or severe allergic rhinitis flare-ups, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Multi-Symptom Cold and Flu

Eligibility and Restrictions for Use

Who Can and Cannot Use Sinutab 3-Way?

This section outlines the population eligibility rules for Sinutab 3-Way (Ibuprofen and Pseudoephedrine Hydrochloride) as defined by official regulatory documentation. These rules determine who is permitted or prohibited from using the medicine under standard labeled conditions.

Populations for Whom Use is Contraindicated

Use is strictly contraindicated (prohibited) in the following groups, primarily due to the combined risk profile of its active ingredients:

  • Age: Children under 12 years of age.
  • Hypersensitivity: Patients with known allergy to Ibuprofen, Pseudoephedrine, Aspirin, or any other NSAID.
  • Pregnancy/Lactation: Women who are pregnant from 20 weeks onwards (third trimester) and lactating (breastfeeding) women.
  • Cardiovascular Disease: Patients with pre-existing severe or uncontrolled hypertension or serious heart disease (e.g., heart failure, ischaemic heart disease).
  • Gastrointestinal History: Individuals with an active or history of recurrent stomach ulcers, perforation, or bleeding.
  • Organ Function: Patients with severe renal impairment (kidney disease) or severe hepatic impairment (liver disease).
  • Drug Interactions: Patients currently taking a Monoamine Oxidase Inhibitor (MAOI) or within 14 days of stopping MAOI treatment.

Populations with Restricted or Conditional Use

The medicine should only be used with special caution in certain groups, including the elderly (due to increased risk of GI adverse reactions) and patients with a history of asthma or other Gastrointestinal diseases (e.g., ulcerative colitis or Crohn's disease).

What should I know about interactions with other medicines?

Official Interaction Profile

The interactions documented for this combination medicine (Ibuprofen and Pseudoephedrine) are governed by regulatory restrictions concerning combined risks to the cardiovascular and gastrointestinal systems.

Category Interaction Restriction
Strictly Contraindicated Monoamine Oxidase Inhibitors (MAOIs), including Linezolid, due to risk of hypertensive crisis. Do not use within 14 days of stopping an MAOI.
Other NSAIDs or Ibuprofen-containing medicines, due to heightened risk of gastrointestinal bleeding and thrombotic events.
Ergot Alkaloids, due to pharmacodynamic synergism enhancing vasoconstricting effects.

Clinically Significant Pharmacodynamic Effects

  • Anticoagulants and Antiplatelet Agents: Co-administration significantly increases the documented risk of serious bleeding complications due to Ibuprofen's effects.
  • Antihypertensive Agents: The Pseudoephedrine component may antagonistically diminish the therapeutic effect of medicines for blood pressure management, such as Beta-blockers or ACE inhibitors, as stated in official labeling.
  • Exposure-Altering Agents: Ibuprofen can increase the plasma concentration of certain agents, including Lithium and Digoxin, as a result of reduced renal clearance, a pharmacokinetic effect documented in official prescribing information.
  • Alcohol: Consumption is officially noted to increase the risk of gastrointestinal irritation and bleeding associated with the Ibuprofen component.
  • Population Note: Caution is noted for elderly patients, who have a heightened risk of severe gastrointestinal adverse reactions when this medicine is combined with other interacting substances.

Mechanism of Action

The Sinutab 3-Way formulation utilizes a multi-compound cascade of actions, targeting three distinct physiological pathways.

Inhibition of Central Prostaglandin Synthesis

Paracetamol blocks prostaglandin synthesis within the central nervous system, which is believed to modulate the hypothalamic set point for thermoregulation. The resulting reduction in prostaglandin E2 concentration contributes to the drug's central action.

H1 Receptor Competitive Antagonism

Chlorpheniramine maleate functions as a competitive antagonist at peripheral H1 receptors, preventing the binding and subsequent activation of histamine. This intervention modifies the cellular response to locally released histamine.

Alpha-Adrenergic Agonism and Local Vasoconstriction

Pseudoephedrine hydrochloride, an alpha-adrenergic agonist, initiates potent vasoconstriction in the arterioles and capacitance vessels of the nasal mucosa. This action results in reduced tissue edema and increased patency of the nasal airway, a direct physiological consequence of the drug's localized effect.

Dosage and Administration Information

The administration of Sinutab 3-Way, a fixed-dose combination product, focuses on adherence to dose, interval, and duration limits. The medication is formulated for oral administration as a fixed-dose combination of 200 mg Ibuprofen and 30 mg Pseudoephedrine HCl per unit.

The standard dosing specifies an initial dose of 1 unit, which may be increased to 2 units if symptoms do not adequately respond. Dosing is regulated by a time-based frequency, permitting a repeat dose only after a minimum of 4 to 6 hours have passed. This schedule must adhere to a strict maximum daily intake of 6 units in any 24-hour period.

Official Administration Guidelines

Instruction Domain Stipulation
Route of Administration Oral route only.
Dosing Schedule 1 or 2 units every 4 to 6 hours; maximum of 6 units per 24 hours.
Administration Context May be taken with food or milk to improve gastric tolerance.
Age-Group Rule Use is restricted to individuals 12 years of age and older.
Duration Constraint Maximum duration of treatment is 3 days for fever and 5 to 7 days for general symptoms.

Connection to the overall use protocol

The usage protocol mandates that the smallest effective dose be utilized for the shortest necessary duration to achieve management. This structured approach ensures the medication is confined to intermittent, short-term use within defined boundaries.

Recent Clinical Evidence

Sinutab 3-Way: Recent Clinical Evidence

Clinical research on combination therapies for the common cold, such as those containing an analgesic (like acetaminophen), a decongestant (like pseudoephedrine), and an antihistamine (like chlorpheniramine), focuses on the relief of combined symptoms.

Reviews of randomized controlled trials suggest that these fixed combinations may provide a modest overall beneficial effect in adults and older children experiencing cold and flu-like symptoms. The effect is typically assessed based on participants' subjective reports of symptom severity and global well-being over a short-term follow-up period.

Individual components of the combination address specific symptoms studied in trials:

  • Acetaminophen: Included primarily to address fever and pain (such as headache or body aches) associated with respiratory illnesses.
  • Pseudoephedrine: Research suggests this ingredient is associated with temporary relief of nasal and sinus congestion by constricting blood vessels in the nasal passages.
  • Chlorpheniramine: Studies have investigated its effect on reducing symptoms related to the body’s histamine response, such as sneezing, runny nose, and watery eyes.

Considerations and Research Gaps

The benefits observed in adults must be balanced against the risk of potential adverse effects, as some trials report higher rates of side effects compared to placebo. Evidence related to the effectiveness of these combination medications in young children (under six years old) is limited, and such use is not supported by current research findings.

Key Studies & References

  1. The Common Cold: A Review of OTC Options - U.S. Pharmacist

Frequently Asked Questions (FAQ)

Common questions about Sinutab 3-Way (FAQ)

Q: What is the intended use of Sinutab 3-Way?

According to the official product information, Sinutab 3-Way is intended for temporary relief of symptoms associated with the common cold, hay fever, or other upper respiratory allergies. Specifically, it works to relieve minor aches and pains, headaches, nasal congestion, and can help reduce fever.

Q: Can I take Sinutab 3-Way if I am allergic to any component?

Regulatory documents state that Sinutab 3-Way should not be used if you have a known allergy or hypersensitivity to its active ingredients (acetaminophen, pseudoephedrine hydrochloride, or chlorpheniramine maleate) or any of the non-active components. Using the product when allergic is listed as a contraindication in the official safety information.

Q: What are the common side effects of Sinutab 3-Way?

Studies and official information indicate that common side effects can include drowsiness, dizziness, nervousness, or difficulty sleeping. It is also possible to experience dry mouth, nose, or throat. The official documentation states that if effects become severe or persistent, seeking advice from a healthcare professional is recommended.

Q: Does Sinutab 3-Way cause drowsiness?

Yes, official product information notes that Sinutab 3-Way may cause drowsiness because it contains chlorpheniramine maleate, which is an antihistamine. Because of this potential effect, official product information includes warnings regarding tasks that require full mental alertness, such as driving or operating machinery.

Q: How soon can I expect relief after taking Sinutab 3-Way?

Official information indicates that the active ingredients in Sinutab 3-Way are typically absorbed relatively quickly after a recommended dose. While specific onset times can vary by person, relief may be experienced soon after administration, corresponding to the time it takes for the active ingredients to be absorbed.

Q: Can I use Sinutab 3-Way for children?

Regulatory guidance specifically states that Sinutab 3-Way should not be given to children under the age of 12 years. The official product labeling provides specific dosage instructions for different age groups above 12. For children younger than this age, consulting with a healthcare provider for appropriate alternatives is generally recommended by official safety standards.

Q: Is it safe to take this medicine with blood pressure medication?

According to the official product information, Sinutab 3-Way contains pseudoephedrine, a decongestant that can affect blood pressure. Therefore, regulatory documents advise against combining this medicine with certain high blood pressure or heart medication without consulting a healthcare professional. This statement is included as a precaution against potential drug interactions.

How should Sinutab 3-Way be stored and disposed of?

How to Store and Dispose of Sinutab 3-Way

The storage and disposal of this medication are governed by official regulatory requirements to ensure product quality and safety.

Storage Requirements

Condition Requirement
Temperature Range Store at controlled room temperature, 20 C to 25 C (68 F to 77 F); avoid excessive heat and freezing.
Protection Keep away from direct light and moisture.
Child Safety Must be stored out of the reach of children.
Packaging Do not use if the tamper-evident blister unit is torn or broken. Use by the expiration date.

Disposal Instructions

Unused or expired Sinutab 3-Way should not be flushed down a toilet or poured down a sink. The required disposal methods include utilizing a local drug take-back program or securely disposing of the product in the household trash. For household disposal, the medicine must first be mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a container or bag.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagSouth Africa

Equivalent of Sinutab 3-Way found in:

A-Z Index: